Investment Rating - The investment rating for the company is "Buy" and is maintained [12] Core Insights - Smoore International is the largest electronic vaporizer supplier globally, with growth potential unlocked by its technology positioning in HNB (Heated Not Burn) products [3][6] - The company's core business is recovering, benefiting from regulatory shifts in the industry and increasing market share among major clients [3][6] - The HNB business is expected to see significant growth, with a projected annual growth rate in the double digits and a current global penetration rate of less than 6% [3][7] Summary by Sections Introduction - Smoore International leverages its R&D advantages to launch HNB products, marking a new phase in the industry [6][17] - The company has transitioned from a pure equipment supplier to a tobacco business model, opening new growth avenues [6][17] Core Business - The HNB segment is poised for accelerated development, with a low penetration rate and high barriers to entry, indicating substantial growth potential [7][28] - The collaboration with British American Tobacco to launch Glo Hilo combines both companies' strengths, enhancing market competitiveness [7][28] Performance Outlook - The revenue-sharing model for Glo Hilo is expected to yield significant profits, with projections estimating annual profits for Smoore's HNB business to reach 6-7 billion RMB if market penetration increases [8][9] - The U.S. market presents a significant opportunity, with potential market size increases if HNB penetration rises to 15% [8][37] Traditional Business - The U.S. vaping market is expected to grow from $19.81 billion in 2021 to $27.03 billion in 2024, with a CAGR of 11% [9][20] - Regulatory changes in the U.S. are becoming more favorable, allowing for a recovery in the vaporizer business [9][20] Long-term Strategic Direction - The company is diversifying into medical and beauty vaporization, aiming for long-term growth across multiple sectors [10][19]

Core Viewpoint - The company's 1H25 performance aligns with expectations, showing revenue growth but a decline in net profit, indicating a mixed financial outlook amid evolving market conditions [1][2]. Financial Performance - Revenue for 1H25 reached 6.01 billion, an 18.3% year-on-year increase, while net profit attributable to shareholders was 500 million, a 30.8% decline. Adjusted net profit after stock incentive expenses was 740 million, down 2.1% [1]. - The company declared an interim dividend of 0.2 HKD per share, with a payout ratio of 225.1%, significantly higher than the 38.7% in 1H24, indicating increased shareholder returns [1]. Market Trends - The ToB revenue grew by 19.5% to 4.739 billion, driven by strong performance in Europe and potential improvements in the U.S. market due to stricter regulations [1]. - In Europe, revenue surged by 38% to 2.73 billion, benefiting from regulatory changes that favored compliant companies [1]. - U.S. revenue increased by 1.5% to 1.89 billion, with expectations of continued improvement as enforcement tightens [1]. - Domestic revenue, however, saw a decline of 6.1% to 120 million [1]. Product Development - The ToC revenue rose by 14.1% to 1.274 billion, with significant growth in the APV segment, particularly in Europe, where new product launches are driving user conversion [2]. - The APV revenue in Europe and the U.S. was 1.07 billion and 170 million, respectively, with declines of 15.1% and 6.7% [2]. - The nebulization beauty segment experienced a remarkable growth of 2595% to 30.618 million, with over 10,000 C-end users and more than 100 B-end partnerships established [2]. Profitability and Costs - The overall gross margin remained stable, decreasing slightly by 0.5 percentage points to 37.3%. However, the net profit margin fell by 5.9 percentage points to 8.3%, and adjusted for stock incentive expenses, it decreased by 1.2 percentage points to 12.3% [2]. - Sales expense ratio increased by 0.8 percentage points to 8.2% due to heightened investment in self-owned brands, while R&D expense ratio decreased by 2.9 percentage points to 12% [2]. - Management expenses rose significantly by 15.5 percentage points to 22.2%, primarily due to increased stock incentive costs [2]. Growth Outlook - The HNB segment is expected to accelerate globally, with Glo Hilo's market share in Japan increasing by 1.5% during its sales period, indicating strong growth potential [3]. - The regulatory environment for vaping products in Europe and the U.S. is expected to lead to a more standardized industry, allowing the company to recover market share and continue growing [3]. - The company is also focusing on developing nebulization medical products and expanding its nebulization beauty segment domestically, which opens up additional growth opportunities [3]. Profit Forecast and Valuation - The company maintains its profit forecast and industry outperform rating, with a target price reflecting a 4% upside from the current stock price [3].

Core Viewpoint - Zheshang Securities maintains a "Buy" rating for Smoore International (06969.HK), highlighting the favorable regulatory environment for HNB products compared to vaping products, which is expected to accelerate market penetration [1] Group 1: Market Position and Competitive Landscape - The competitive landscape for HNB products is more favorable than that for vaping products, suggesting a better market position for Smoore International [1] - The product experience of HNB is improving, which is anticipated to enhance penetration rates [1] Group 2: Future Growth Projections - Smoore International is expected to achieve revenues of 12.89 billion, 15.31 billion, and 18.35 billion from 2025 to 2027 [1] - The projected net profit attributable to the parent company is forecasted to be 1.32 billion, 2.00 billion, and 2.73 billion for the same period [1] Group 3: Strategic Developments - The launch of British American Tobacco's new generation GloHilo product in Japan on September 1 is expected to benefit Smoore International as a core supplier [1] - The medical business is identified as the next important growth area for Smoore International [1]

Investment Rating - The industry investment rating is "Overweight (Maintain)" [1] Core Insights - The report highlights the potential growth in the HNB (Heated Not Burned) market, particularly with the launch of Glo Hilo in Japan, which is expected to enhance sales performance and accelerate market penetration [4][5] - The report indicates that British American Tobacco's (BAT) revenue for the first half of 2025 is projected to grow by 1%-2%, driven by strong performance in the U.S. market despite an overall decline in industry retail sales [5] - The report emphasizes the importance of technological barriers in the HNB product segment, particularly in heating technology and flavoring processes, which are crucial for enhancing user experience [4] Industry Performance Over the Last Twelve Months - The industry has shown a relative return of 4.33% over the past month, 4.58% over the past three months, and 5.82% over the past twelve months compared to the CSI 300 index [2] - Absolute returns for the same periods are 4.83%, 2.59%, and 13.97% respectively [2] Related Research Reports - Previous reports include insights on the light industry manufacturing sector and the anticipated release of new products in the smart glasses market [3] - The report also references the performance outlook for British American Tobacco in the first half of 2025, focusing on new product launches and market strategies [5]